Even though our current experimental systems were not able to pinpoint how CADM1 expression might compromise EBV-associated lymphomagenesis in the absence of XIAP, it might stimulate immune control, possibly by innate immunity in secondary lymphoid tissues to prevent EBV-positive lymphomas in XLP-2 patients. The gene discussed is CADM1; the disease is lymphoma.